AdAlta (1AD) 2019年年度报告「ASX」.pdf

1、 ADALTA LTD ABN 92 120 332 925 FINANCIAL REPORT FOR THE YEAR ENDED 30 JUNE 2019 ADALTA LTD ABN 92 120 332 925 CORPORATE DIRECTORY DIRECTORS Dr Paul MacLeman Ms Samantha Cobb(resigned 25 August 2019)Dr James Williams Ms Elizabeth McCall Dr John Chiplin Dr Robert Peach Dr Rosalind Wilson(appointed 1 A

2、ugust 2019)COMPANY SECRETARY Cameron Jones REGISTERED OFFICE Unit 15 2 Park Drive Bundoora VIC 3083 Telephone:+61 3 9479 5159 Email:.au Website:.au STOCK EXCHANGE Australian Securities Exchange Limited Level 4,North Tower Rialto 525 Collins Street Melbourne VIC 3000 ASX CODE 1AD SHARE REGISTRY Autom

3、ic Registry Services Level 5 126 Phillip Street Sydney NSW 2000 Telephone:1300 288 664 Website:.au AUDITOR Butler Settineri(Audit)Pty Ltd Unit 16,First Floor 100 Railway Road Subiaco WA 6008 BANKERS Westpac Banking Corporation SOLICITORS Lander&Rogers Level 12,600 Bourke Street Melbourne VIC 3000 AD

4、ALTA LTD ABN 92 120 332 925 CONTENTS Page No.Directors Report 2 Auditors Independence Declaration 20 Corporate Governance Statement 21 Statement of Profit or Loss and Other Comprehensive Income 22 Statement of Financial Position 23 Statement of Changes in Equity 24 Statement of Cash Flows 25 Notes t

5、o the Financial Statements 26 Directors Declaration 45 Independent Auditors Report 46 Shareholder Information 51 2 Adalta Limited Annual Report 2019 CHAIRMANS LETTER During the year AdAlta hit many major milestones required for us to commence the first-in-human clinical trial for our lead fibrosis t

6、herapeutic,AD-214.We are on track to meet this major inflection point in January 2020.It is my pleasure therefore to start the FY2019 annual report looking back upon a year of significant de-risking of the AdAlta technology.After many years of developing both AD-214 and the i-body platform,through w